These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 10966743

  • 1. 4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors.
    Wissner A, Berger DM, Boschelli DH, Floyd MB, Greenberger LM, Gruber BC, Johnson BD, Mamuya N, Nilakantan R, Reich MF, Shen R, Tsou HR, Upeslacis E, Wang YF, Wu B, Ye F, Zhang N.
    J Med Chem; 2000 Aug 24; 43(17):3244-56. PubMed ID: 10966743
    [Abstract] [Full Text] [Related]

  • 2. 4-Anilino-7,8-dialkoxybenzo[g]quinoline-3-carbonitriles as potent Src kinase inhibitors.
    Berger DM, Dutia M, Birnberg G, Powell D, Boschelli DH, Wang YD, Ravi M, Yaczko D, Golas J, Lucas J, Boschelli F.
    J Med Chem; 2005 Sep 22; 48(19):5909-20. PubMed ID: 16161995
    [Abstract] [Full Text] [Related]

  • 3. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.
    Tsou HR, Overbeek-Klumpers EG, Hallett WA, Reich MF, Floyd MB, Johnson BD, Michalak RS, Nilakantan R, Discafani C, Golas J, Rabindran SK, Shen R, Shi X, Wang YF, Upeslacis J, Wissner A.
    J Med Chem; 2005 Feb 24; 48(4):1107-31. PubMed ID: 15715478
    [Abstract] [Full Text] [Related]

  • 4. Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents.
    Wissner A, Brawner Floyd MB, Rabindran SK, Nilakantan R, Greenberger LM, Shen R, Wang YF, Tsou HR.
    Bioorg Med Chem Lett; 2002 Oct 21; 12(20):2893-7. PubMed ID: 12270171
    [Abstract] [Full Text] [Related]

  • 5. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785).
    Discafani CM, Carroll ML, Floyd MB, Hollander IJ, Husain Z, Johnson BD, Kitchen D, May MK, Malo MS, Minnick AA, Nilakantan R, Shen R, Wang YF, Wissner A, Greenberger LM.
    Biochem Pharmacol; 1999 Apr 15; 57(8):917-25. PubMed ID: 10086326
    [Abstract] [Full Text] [Related]

  • 6. 4-anilino-3-quinolinecarbonitriles: an emerging class of kinase inhibitors.
    Boschelli DH.
    Curr Top Med Chem; 2002 Sep 15; 2(9):1051-63. PubMed ID: 12171571
    [Abstract] [Full Text] [Related]

  • 7. 4-Anilino-3-cyanobenzo[g]quinolines as kinase inhibitors.
    Zhang N, Wu B, Wissner A, Powell DW, Rabindran SK, Kohler C, Boschelli F.
    Bioorg Med Chem Lett; 2002 Feb 11; 12(3):423-5. PubMed ID: 11814812
    [Abstract] [Full Text] [Related]

  • 8. Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor.
    Smaill JB, Showalter HD, Zhou H, Bridges AJ, McNamara DJ, Fry DW, Nelson JM, Sherwood V, Vincent PW, Roberts BJ, Elliott WL, Denny WA.
    J Med Chem; 2001 Feb 01; 44(3):429-40. PubMed ID: 11462982
    [Abstract] [Full Text] [Related]

  • 9. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.
    Smaill JB, Rewcastle GW, Loo JA, Greis KD, Chan OH, Reyner EL, Lipka E, Showalter HD, Vincent PW, Elliott WL, Denny WA.
    J Med Chem; 2000 Apr 06; 43(7):1380-97. PubMed ID: 10753475
    [Abstract] [Full Text] [Related]

  • 10. Synthesis and structure-activity relationship of 4-(2-aryl-cyclopropylamino)-quinoline-3-carbonitriles as EGFR tyrosine kinase inhibitors.
    Pannala M, Kher S, Wilson N, Gaudette J, Sircar I, Zhang SH, Bakhirev A, Yang G, Yuen P, Gorcsan F, Sakurai N, Barbosa M, Cheng JF.
    Bioorg Med Chem Lett; 2007 Nov 01; 17(21):5978-82. PubMed ID: 17827009
    [Abstract] [Full Text] [Related]

  • 11. Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors.
    Liu LT, Yuan TT, Liu HH, Chen SF, Wu YT.
    Bioorg Med Chem Lett; 2007 Nov 15; 17(22):6373-7. PubMed ID: 17889528
    [Abstract] [Full Text] [Related]

  • 12. 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity.
    Tsou HR, Mamuya N, Johnson BD, Reich MF, Gruber BC, Ye F, Nilakantan R, Shen R, Discafani C, DeBlanc R, Davis R, Koehn FE, Greenberger LM, Wang YF, Wissner A.
    J Med Chem; 2001 Aug 16; 44(17):2719-34. PubMed ID: 11495584
    [Abstract] [Full Text] [Related]

  • 13. Tyrosine kinase inhibitors against EGF receptor-positive malignancies.
    Sudbeck EA, Ghosh S, Liu XP, Zheng Y, Myers DE, Uckun FM.
    Methods Mol Biol; 2001 Aug 16; 166():193-218. PubMed ID: 11217368
    [No Abstract] [Full Text] [Related]

  • 14. Irreversible inhibition of epidermal growth factor receptor activity by 3-aminopropanamides.
    Carmi C, Galvani E, Vacondio F, Rivara S, Lodola A, Russo S, Aiello S, Bordi F, Costantino G, Cavazzoni A, Alfieri RR, Ardizzoni A, Petronini PG, Mor M.
    J Med Chem; 2012 Mar 08; 55(5):2251-64. PubMed ID: 22280453
    [Abstract] [Full Text] [Related]

  • 15. Synthesis and Src kinase inhibitory activity of a series of 4-phenylamino-3-quinolinecarbonitriles.
    Boschelli DH, Wang YD, Ye F, Wu B, Zhang N, Dutia M, Powell DW, Wissner A, Arndt K, Weber JM, Boschelli F.
    J Med Chem; 2001 Mar 01; 44(5):822-33. PubMed ID: 11262092
    [Abstract] [Full Text] [Related]

  • 16. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2).
    Wissner A, Overbeek E, Reich MF, Floyd MB, Johnson BD, Mamuya N, Rosfjord EC, Discafani C, Davis R, Shi X, Rabindran SK, Gruber BC, Ye F, Hallett WA, Nilakantan R, Shen R, Wang YF, Greenberger LM, Tsou HR.
    J Med Chem; 2003 Jan 02; 46(1):49-63. PubMed ID: 12502359
    [Abstract] [Full Text] [Related]

  • 17. Identification of 4-anilino-3-quinolinecarbonitrile inhibitors of mitogen-activated protein/extracellular signal-regulated kinase 1 kinase.
    Mallon R, Feldberg L, Kim S, Collins K, Wojciechowicz D, Kohler C, Kovacs D, Discafani C, Zhang N, Wu B, Floyd B, Powell D, Berger D.
    Mol Cancer Ther; 2004 Jun 02; 3(6):755-62. PubMed ID: 15210862
    [Abstract] [Full Text] [Related]

  • 18. 4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity.
    Liu F, Tang B, Liu H, Li L, Liu G, Cheng Y, Xu Y, Chen W, Huang Y.
    Anticancer Agents Med Chem; 2016 Jun 02; 16(12):1652-1664. PubMed ID: 27039919
    [Abstract] [Full Text] [Related]

  • 19. Synthesis and structure-activity relationships of 3-cyano-4-(phenoxyanilino)quinolines as MEK (MAPKK) inhibitors.
    Zhang N, Wu B, Powell D, Wissner A, Floyd MB, Kovacs ED, Toral-Barza L, Kohler C.
    Bioorg Med Chem Lett; 2000 Dec 18; 10(24):2825-8. PubMed ID: 11133101
    [Abstract] [Full Text] [Related]

  • 20. Synthesis, antitumor evaluation and docking study of novel 4-anilinoquinazoline derivatives as potential epidermal growth factor receptor (EGFR) inhibitors.
    Rao GW, Xu GJ, Wang J, Jiang XL, Li HB.
    ChemMedChem; 2013 Jun 18; 8(6):928-33. PubMed ID: 23640754
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.